InVivo in the News

InVivo announces patient death in study, says deemed to be unrelated to scaffold

Published: July 12, 2016

(Fly On The Wall) InVivo Therapeutics announced that the 9th and 10th patients have been implanted with the Neuro-Spinal Scaffold™ in the INSPIRE study. The 9th patient was implanted at Vidant Medical Center, a Level 1 trauma center located in Greenville, North Carolina.

View Article
InVivo Therapeutics names Christina Morrison to its board of directors: 4 points

Published: June 8, 2016

(Becker’s Spine Review) Cambridge, Mass.-based InVivo Therapeutics named Christina Morrison to its board of directors.

View Article
6 Breakout Stocks Under $10 Set to Soar

Published: May 31, 2016

(TheStreet) InVivo Therapeutics (NVIV) , a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. This stock traded up 4.3% to $6.68 in Friday’s trading session…

View Article
InVivo Therapeutics shares mission on radio broadcast — 3 notes

Published: May 26, 2016

(Becker’s Spine Review) WBZ NewsRadio 1030 featured InVivo Therapeutics on its radio broadcast.

View Article
InVivo Therapeutics receives Notice of Allowance for SCI polymeric implant patent — 3 things to know

Published: May 18, 2016

(Becker’s Spine Review) The U.S. Patent and Trademark Office issued InVivo Therapeutics a Notice of Allowance for the U.S. Patent Application, “Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries.”

View Article
InVivo adds 20th clinical site to Inspire study

Published: May 11, 2016

(MassDevice) InVivo Therapeutics (NSDQ:NVIV) said today it added Philadelphia’s Hospital of the University of Pennsylvania as a site in the Inspire study of its neuro-spinal scaffold, bringing the total number of sites up to 20.

View Article
InVivo Therapeutics adds Penn Medicine as INSPIRE study site: 4 points

Published: May 11, 2016

(Becker’s Spine Review) InVivo Therapeutics added Philadelphia-based University of Pennsylvania as a clinical site for the INSPIRE study.

View Article
An Absent Life Science Blogger’s Backstory

Published: May 3, 2016

(Life Science Reader) Let me tell you what I’ve been doing the last few months and why you haven’t seen a blog from me during all that time. Two activities have accounted for most of my workload — writing and travel. But of the two, writing has taken the lion’s share. I don’t mean the kind of writing I’m doing now, scribing down thoughts right out of my memory and imagination. I mean the sort of writing where most of the work takes place well before I press the first key for the first letter in the first draft. One series of articles now underway has so far required 16 interviews, some by phone, others on the road.

View Article
4th patient in INSPIRE study experiences AIS grade improvement: 5 things to know

Published: April 28, 2016

(Becker’s Spine Review) Another implanted patient in InVivo Therapeutics’ INSPIRE study improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury, according to pharmiweb.com.

View Article
Fourth patient converts from complete to incomplete spinal cord injury in InVivo trial

Published: April 26, 2016

(MassDevice) InVivo Therapeutics (NSDQ:NVIV) said today 4th patient in the Inspire study of its Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury.

View Article

The articles contained in this section of the website are written and published by persons not affiliated with InVivo. The views expressed in these articles are those of the author(s) and do not reflect the views of InVivo. Additionally, the information contained in these articles may not be current. InVivo disclaims any obligation to correct or to update the information contained in these articles.